At present, routine biomarker screening (CEA, CA72-4, and CA19-9) is the recommended approach for GC diagnosis and evaluation of therapeutic efficiency, considering the invasive diagnostic strategies such as gastroscope always lead to severe pain and inconvenience8,60 In this study, we proposed plasma TrxR activity as a novel, independent and efficient biomarker for GC diagnosis and therapeutic evaluation. Here, CEACAM5 is linked to gastric cancer.